NCT00000753View on ClinicalTrials.gov

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1995

Conditions
HIV Infections
Interventions
DRUG

Atevirdine mesylate

DRUG

Zidovudine

DRUG

Zalcitabine

DRUG

Didanosine

Trial Locations (6)

14642

Univ. of Rochester ACTG CRS, Rochester

33136

Univ. of Miami AIDS CRS, Miami

43210

The Ohio State Univ. AIDS CRS, Columbus

63112

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

90033

USC CRS, Los Angeles

Unknown

Washington U CRS, St Louis

Sponsors

Collaborators (2)

Upjohn
Glaxo Wellcome
All Listed Sponsors
collaborator

Upjohn

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000753 - A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC | Biotech Hunter | Biotech Hunter